The anti-tumour efficacy of adenovirus coding for an IL-2 variant (vIL-2) protein—Ad5/3-E2F-d24-vIL2 was evaluated in immunocompetent hamsters bearing pancreatic tumours [189]. This evidence concerns the gene EZR and pancreatic neoplasm.